MHRA paediatric investigation plan
Brukinsa (ZANUBRUTINIB)
MHRA paediatric investigation plan MHRA-101079-PIP01-23-M01 (update) · Waiver
Key facts
| PIP number | MHRA-101079-PIP01-23-M01 (update) |
|---|---|
| Product names | Brukinsa |
| Active substances | ZANUBRUTINIB |
| Therapeutic areas | Oncology |
| Conditions | Treatment of lymphoplasmacytic lymphoma, Treatment of mature B-cell neoplasms (excluding lymphoplasmacytic lymphoma) |
| Decision | W: decision granting a waiver in all age groups for the listed condition(s). |
| Published | Dec 19, 2023 |
| MHRA record | cms.mhra.gov.uk |
About MHRA paediatric investigation plans
A paediatric investigation plan sets out the studies a company must run in children to support authorisation of a medicine in the UK, or records a waiver or deferral.
Source: UK Medicines and Healthcare products Regulatory Agency (MHRA). Contains public sector information licensed under the Open Government Licence v3.0 · Source date: